Which clinical PH groups can be distinguished?
Learn more about the clinical path of PAH!
Pulmonary Arterial Hypertension (PAH) - video 2
This video is part of a collection of 8 clinical key questions that are being addressed by Prof. dr. Galiè from the university of Bologna, Italy. These questions cover the clinical behavior, diagnostics and treatment path of pulmonary arterial hypertension (PAH), which Prof. dr. Galiè thoroughly elaborates on.
This educational series of videos aims to provide more insights into the pathophysiology and management of pulmonary arterial hypertension (PAH). By addressing some of the key questions viewers will receive a compact update on current understanding and guidelines of PAH
- Q1: What is the underlying pathophysiology of PAH and what are its characteristics?
- Q2: Which clinical pulmonary hypertension (PH) groups can be distinguished?
- Q3: How common is PAH and what are its risk factors?
- Q4: How is PAH diagnosed?
- Q5: How can PH patients be functionally classified?
- Q6: How is the prognosis of PAH established?
- Q7: Which treatment options can be pursued and which drugs are approved for PAH?
- Q8: How do we follow-up PAH patients non-responsive to therapy and how can therapy be optimized?
Prof Nazzareno Galiè, Institute of Cardiology, University of Bologna, Bologna, Italy
Nazzareno Galiè, MD, heads the Pulmonary Hypertension Centre at the Institute of Cardiology and is Associate Professor of Cardiology at the Medical Faculty of the University of Bologna, Italy. He also teaches at the Postgraduate Medical Schools of Cardiology, Pulmonary Diseases, and Rheumatology at the University of Bologna. He is Director of the International Master Degree in Pulmonary Vascular Diseases of the University of Bologna
He is past-Chairman of the working group on pulmonary circulation of the European Society of Cardiology and of the joint task force of the European Society of Cardiology and the European Respiratory Society for the guidelines on pulmonary hypertension
This educational video series is funded via an unrestricted educational grant provided by Pfizer